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Abstract: Accumulating evidence suggests that ubiquitin E3 ligases are involved in cancer 
development as their mutations correlate with genomic instability and genetic susceptibility 
to cancer. Despite significant findings of cancer-driving mutations in the BRCA1 gene, 
estrogen receptor (ER)-positive breast cancers progress upon treatment with DNA 
damaging-cytotoxic therapies. In order to understand the underlying mechanism by which 
ER-positive breast cancer cells develop resistance to DNA damaging agents, we employed 
an estrogen receptor agonist, Erb-041, to increase the activity of ERβ and negatively 
regulate the expression and function of the estrogen receptor α (ERα) in MCF-7 breast 
cancer cells. Upon Erb-041-mediated ERα down-regulation, the transcription of an ERα 
downstream effector, BCA2 (Breast Cancer Associated gene 2), correspondingly decreased. 
The ubiquitination of chromatin-bound BCA2 was induced by ultraviolet C (UVC) 
irradiation but suppressed by Erb-041 pretreatment, resulting in a blunted DNA damage 
response. Upon BCA2 silencing, DNA double-stranded breaks increased with Rad51  
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up-regulation and ataxia telangiectasia mutated (ATM) activation. Mechanistically,  
UV-induced BCA2 ubiquitination and chromatin binding were found to promote DNA 
damage response and repair via the interaction of BCA2 with ATM, γH2AX and Rad51. 
Taken together, this study suggests that Erb-041 potentiates BCA2 dissociation from 
chromatin and co-localization with Rad51, resulting in inhibition of homologous 
recombination repair. 
Keywords: BCA2; DNA damage response; Erb-041; Rad51; UVC 
 
1. Introduction 
Breast cancer is the most frequently diagnosed site-specific cancer in the female population in the 
world. Its mortality rate has fallen with earlier diagnosis, and improvements in medical treatments, 
including surgery, chemotherapy, radiotherapy and anti-hormonal treatment. By blocking estrogen 
receptors (ER), the proliferation and metastatic potential of early stage breast cancers can be inhibited 
by aromatase inhibitors and selective ER modulators, such as Arimidex, Aromasin, Tamoxifen and 
Faslodex [1]. The reduced production of estrogen as well as competitive drug binding with ERα 
(estrogen receptor α) prevents ER−estrogen complexes from forming and translocating to the nuclei to 
trigger the transcription of growth-promoting genes. As ERα transactivates genes that promote 
accelerated DNA synthesis and cell proliferation, high levels of estrogens also increase DNA damage 
and the risk of breast and ovarian cancer. Nevertheless, estrogen also promotes the transcription of 
BRCA1 via binding with an ERα/p300 complex, and facilitates DNA double-stranded break (DSB) 
repair by stimulating the formation of a complex among ERα, CREB-binding protein and BRCA1 [2]. 
It has been shown that the ubiquitin E3 ligase activity of BRCA1 is critical for homologous 
recombination (HR) repair [3]. With respect to the high propensity of BRCA mutations in familial 
breast cancer, the facilitative role of BRCA1 in DNA damage response and repair is thought to be 
facilitated by other breast cancer-associated ubiquitin E3 ligases. To find out whether the ERα 
downstream effector, BCA2 (breast cancer-associated gene 2), plays a role in DNA damage response 
(DDR) secondary to increased replication stress upon ERα-enhanced DNA synthesis, Erb-041  
(an agonist of ERβ) was applied to inhibit ERα transcription activity prior to UVC irradiation [4–6]. 
The present study particularly demonstrated the mechanism of Erb-041 action in increasing 
carcinogen-induced DNA damage via the potentiation of BCA2 destabilization and the interaction 
between BCA2 and DDR proteins. 
Activation of ERβ has proved to be therapeutically valuable for inhibiting ERα-mediated cell 
proliferation through the enhancement of ERα/β heterodimerization [7,8]. Among many downstream 
effecters of ERα, breast cancer-associated gene 2 (BCA2) was found to be trans-activatable by ERα  
and correlated with clinical variables, such as lymph node status and regional recurrence [9,10].  
The correlation between the nuclear expression of BCA2 and positive ER status suggests that BCA2 
may be involved in the adaptation of estrogen-responsive cancers to chronic replication stress by 
upregulating the cells’ DNA repair capability [11]. BCA2 has been characterized as an ubiquitin E3 
ligase, RING-finger protein (RNF115), or Rab7-interacting RING-finger protein (Rabring7) that is 
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overexpressed in more than 50 percent of breast tumors, including ER-negative breast cancers [12].  
It is known that BCA2 promotes breast cancer development in association with ubiquitin-mediated 
degradation of p21Waf1/Cip1 via its E3 ubiquitin ligase activity [13]. In addition, BCA2 was found to 
complex with Rab7 (a cytosolic GTPase) and inhibit cellular endocytosis and lysosomal degradation of 
EGF, leading to EGF stabilization and enhanced cell proliferation [14,15]. However, it is unclear 
whether BCA2 plays a role in DNA damage response (DDR) to increased replication stress associated 
with enhanced cell proliferation, or in response to exogenous DNA damaging agents such as UV  
and X-rays. 
Here, we assess the efficacy of an ERβ agonist as a DNA damage sensitizer in human breast cancer 
cells, using ultraviolet C (UVC) irradiation as an inducer of DNA damage. Compared with cisplatin, 
doxorubicin or X-rays, UVC induces various types of DNA damage, enabling the exploration of the 
effect of Erb-041 on multiple DNA repair pathways, such as ICL (interstrand crosslink) repair, 
homologous recombination repair, non-homologous end joining repair, and base and nucleotide 
excision repair. Based on the findings that the level of Rad51 mRNA is positively correlated to the 
status of estrogen receptors, and that ERβ inhibits homology-directed DNA repair by facilitating 
nuclear interaction between Rad51 and insulin receptor substrate 1 (IRS-1) in ERα-low-expressing 
medulloblastoma, we hypothesize that Erb-041 may potentiate UVC-induced DNA DSBs through HR 
inhibition [16–18]. In HR-directed DNA repair, Rad51 is loaded onto the 3’ ends of DNA DSBs for 
directing a template strand of DNA to a paired strand of homologous DNA molecules [19].  
With assistance from its cofactors, Rad51 forms a helical nucleoprotein filament on DNA to elicit 
DNA strand exchange activity [20–22]. Given that IRS-1 binds ERα, translocates to the nucleus,  
and modulates ERα-dependent transcription at estrogen response elements (ERE), the inhibitory effect 
of ERβ on the transcription activity of ERα may further decrease cell survival via Rad51 inhibition [23]. 
The synthetic ERβ agonist, Erb-041, displays more than a 200-fold greater selectivity for ERβ vs.  
ERα [24]. The agonistic effect of Erb-041 on ERβ was found to increase the growth inhibitory effect of 
Tamoxifen in the combinatory treatment of MCF-7 and T-47D cells [25]. Well-tolerated with few side 
effects, ERβ agonists are currently utilized in clinical trials for the treatment of patients with cancer and 
other inflammatory diseases [26,27]. With the encouraging cancer-suppressing feature of Erb-041,  
we herein describe its in vitro anticancer activity via the modulation of DNA damage response and 
repair as well as its counteractive action on the ERα-BCA2 pathway. 
2. Experimental Section 
2.1. Cell Culture 
MCF-7 and HEK293T/17 cells were maintained in DMEM/F12 (Life Technologies, Grand Island, 
NY, USA) and DMEM (Mediatech Inc., Manassas, VA, USA), respectively. Culture media were 
supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA),  
50 U/mL penicillin and 50 μg/mL streptomycin (Life Technologies) in 5% CO2 at 37 °C in a 
humidified incubator. Prior to addition of siRNA, the complete DMEM/F12 was replaced by reduced 
serum medium Opti-MEM (Life Technologies). 
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2.2. Cell Irradiation 
Cells were exposed to UVC (XL-1000 UV crosslinker, Spectronics Corporation, Westbury, NY, 
USA) at the energy irradiance of 10 J/m2 after the culture media were replaced by phosphate-buffered 
saline (PBS) (Mediatech, Inc., Manassas, VA, USA). Cells were incubated with complete culture 
media immediately following cell irradiation. 
2.3. Antibodies and Drugs 
Anti-BCA2 antibody was kindly acquired from Dr. Arun Seth [11]. Antibodies against FANCD2 
(sc-20022), Rad51 (sc-8349), β Tubulin (sc-9104) and actin (sc-8432) were purchased from Santa Cruz 
(Dallas, TX, USA); histone H2A (ab15653), lamin B1 (ab90576) were purchased from Abcam 
(Cambridge, MA, USA); Phospho-1981Ser-ATM (#4526), phospho-139Ser-γH2AX (#2577) and 
phospho-317Ser-Chk1 (#12302) were purchased from Cell Signaling (Beverly, MA); anti-mouse  
IgG-HRP (A9044), anti-goat IgG-HRP (A5420), anti-rabbit IgG-HRP (A9169), and FLAG M2 (F3165) 
were purchased from Sigma (St. Louis, MO, USA); Alexa Fluor 555 donkey anti-goat IgG (A-21432),  
Alexa Fluor 488 goat anti-mouse (A-10667) and donkey anti-rabbit IgG (A-21206) were purchased 
from Life Technologies. Erb-041 (chemical name: 7-Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol), 
acquired from Dr. Mohammad Athar, was dissolved in ethanol to 40 mM [4]. MG-132 (Selleck 
Chemicals, Houston, TX, USA) was dissolved in DMSO to 20 mM. Further dilution of the stock 
solutions by culture media was performed for cell treatment. 
2.4. Plasmids, siRNAs and Transfection 
Full-length human BCA2 cDNA, provided by Dr. Arun Seth, was cloned as a Not I–Sal I fragment 
from FLAG-tagged pCMV–BCA2 [11]. The vector, pcDNA3-EGFP (plasmid #13031), was acquired 
from Addgene (Cambridge, MA, USA). The siRNAs targeting the BCA2 gene were synthesized by 
Thermo Scientific Dharmacon (Lafayette, CO, USA), and the sequences were 5'-AGACAAUACCAC 
AACAACATT-3' and 5'-CGUCUGAAUAGAAUUAAUUTT-3', respectively. A scrambled siRNA 
sequence, 5'-UAGCGACUAAACCACAUCAAUU-3', was used as the negative control. Transfections 
were performed using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) with protocols 
recommended by the manufacturer. 
2.5. Protein Extraction and Sodium Dodecyl Sulfate−Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Cells were harvested by aspirating the medium and washing twice with cold PBS. Cell lysis was 
accomplished with cytoskeleton (CSK) buffer containing 0.1 M NaCl, 10 mM PIPES (pH 6.8),  
3 mM MgCl2, 1 mM EGTA, 0.1% Triton X-100, 0.3 M sucrose, 1 mM dithiothreitol, 0.1 mM ATP,  
1 mM Na3VO4 and 10 mM NaF supplemented with protease and phosphatase inhibitors (Roche 
Diagnostics, Indianapolis, IN, USA). Cell lysates were scraped and collected into microfuge tubes and 
allowed for 10 min lysis on ice. For extracting chromatin-bound proteins, the detergent-insoluble 
nuclei were separated from the soluble fraction by centrifugation at 3000g for 5 min. The soluble 
fractions were transferred to new microfuge tubes, and the remaining pellets were washed twice with 
CSK buffer. Protein concentrations were measured with Bio–Rad Protein Assay Dye Reagent 
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Concentration (Bio–Rad, Hercules, CA, USA) at 595 nm and aliquoted for mixing with Laemmeli 
sample buffer (Bio–Rad) at equivalent protein contents. Protein denaturation was performed at 95 °C 
for 10 min. Denatured samples were resolved by SDS (sodium dodecyl sulfate)-PAGE (polyacrylamide 
gel electrophoresis) gels and transferred to nitrocellulose membranes by electrophoresis and Trans-Blot 
Turbo systems (Bio–Rad). After transferring to nitrocellulose membranes and blocking with 5% nonfat 
milk, the targeted proteins were immunoblotted with specific antibodies. To probe different target 
proteins on the same membranes, a stripping buffer containing 62.5 mM Tris–HCl (pH 6.8), 2% SDS 
and 0.1 M β-mercaptoethanol was used to strip the primary and secondary antibodies. 
2.6. Immunoprecipitation Assay 
For endogenous protein interaction, cells were treated with MG132 (20 μM) for five hours before 
harvesting. After protein extraction and SDS-PAGE electrophoresis, cell lysates of the soluble fraction 
extracted with CSK buffer were aliquoted equally for incubating with goat serum- or goat anti-BCA2  
antibody-conjugated protein A/G plus agarose (Santa Cruz Biotechnology) overnight at 4 °C, separately. 
The conjugation of the antibody to protein A/G agarose was conducted by adding and mixing 4 μg 
BCA2 antibody and 50 μL protein A/G agarose with 1 mL immunoprecipitation (IP) buffer (25 mM 
Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol) by rotation for two hours 
at 4 °C. The excessive non-conjugated antibody was removed by washing in the IP buffer with 30 s 
centrifugation at 12,000 rpm for three times. 
For cell lysates acquired from the chromatin-bound fraction, DNA digestion was processed with 
RNase-free DNAase I in CSK buffer for 45 min at 37 °C, following the manufacturer’s protocol  
(Fisher Scientific, Pittsburgh, PA, USA) prior to the incubation with goat serum- or goat anti-BCA2 
antibody-conjugated protein A/G plus agarose. To solubilize chromatin-bound proteins, DNAase I-processed 
samples were further mixed with EDTA at the final concentration of 4.5 mM and heated at 65 °C for 
10 min. Afterwards, samples were centrifuged at 12,000 rpm for two minutes to fractionate solubilized 
chromatin-bound proteins in the supernatant. After overnight incubation with goat serum and goat  
anti-BCA2 antibody-conjugated protein A/G plus agarose, IP samples were washed with IP buffer by 
30 s centrifugation at 12,000 rpm three times. The precipitated proteins then were eluted by dissolving 
in 30% (w/v) sarkosyl-containing IP buffer with 30 min rotation at 4 °C, followed by 30 s centrifugation 
at 12,000 rpm. The supernatants were collected and boiled for 10 min with Laemmeli sample buffer, 
and subject to SDS-PAGE electrophoresis. 
2.7. Quantitative Reverse Transcription-Polymerase Chain Reaction 
The mRNA levels of BCA2, ATM, and Rad51 were examined by two-step PCR (polymerase chain 
reaction) in MCF-7 cells. After cell treatment or transfection by siBCA2, total RNAs were prepared 
from cultured cells using TRIzol reagent (Ambion; Life Technologies). Reverse transcription of 1 μg 
of total RNA was performed with the High Capacity RNA-to-cDNA Kit (Applied Biosystems;  
Life Technologies) following the manufacturer’s protocol. The primers for real-time PCR reaction 
were acquired from Bio–Rad and were compatible with the iTaq Universal SYBR Green Supermix 
(Bio–Rad) and CFX96-Real-Time System (C1000 Touch Thermal Cycler, Bio–Rad). PCR on cDNA 
products was performed using the following parameters: pre-denaturation at 95 °C for 30 s, denature at 
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95 °C for 5 s, annealing and elongation at 60 °C for 30 s, and running 50 cycles with a final melt-curve 
analysis set from 65 to 95 °C at a 0.5 °C increment, 2–5 s/step. The folds of changes in target mRNA 
levels were calculated from the Ct (cycle threshold) values of samples in triplicate. 
2.8. Clonogenic Assay 
Cells undergoing log-phase growth were plated at the density of 1000 cells/6 cm dish. Following 
cell attachment at 4 h post-seeding, treatment was carried out and terminated by replacing the 
treatment medium with growth media. Following two weeks of culture, i.e., until the number of 
colonies per dish did not increase with culture time, the cells were washed with PBS and fixed with 
100% methanol for 10 min. The colonies were stained with crystal violet (0.2% crystal violet (w/v)  
in water) for 5 min, and rinsed with PBS. Colonies, composed of 50 cells and more, were counted in 
control and treated dishes and used to calculate the surviving fraction of cells receiving treatment. 
2.9. Cell Cycle Analysis with Fluorescent-Activated Cell Sorting (FACS) 
Cells at 60% confluence were harvested after treatment. The cells were trypsinized, washed,  
and fixed with ice-cold 70% ethanol at −20°C overnight. After PBS washing, cells were incubated with  
40 µg/mL propidium iodide (Life Technologies) and 0.5 µg/mL RNase A (Thermo Scientific) in PBS 
at 37 °C for 30 min, and subjected to flow cytometry performed with a BD FACSCanto II system 
(Beckton–Dickinson, Franklin Lakes, NJ, USA) and FACS Diva v6.1.3 software (BD Biosciences,  
San Jose, CA, USA). Cell cycle distribution was analyzed using the trapezoid shape approximation of 
ModFit (Verity Software House, Inc., Topsham, ME, USA) with linear scaling. 
2.10. Immunofluorescence Staining and Confocal Microscopy 
Cells were seeded in fluoroDish culture plates (World Precision Instruments, Inc., Sarasota, FL, 
USA) and treated with Erb-041 and/or UV at 70% confluence. After irradiation, cells were incubated 
with EdU (5-ethynyl-2'-deoxyuridine), an indicator for DNA synthesis, for 30 min and fixed with 
acetone–methanol, 1:1 (v/v) for 10 min at −20 °C. Following fixation, the samples were washed in 
PBS for 5 min and blocked with 5% milk TBST solution (20 mM Tris base, 0.15 M NaCl and 0.05%  
Tween 20) for 30 min at room temperature. EdU staining was performed following the manufacturer’s 
protocol (Click-iT EdU Alexa Fluor 647 Imaging Kit, Life Technologies). Further incubation of 
samples with the primary antibody against γH2AX was performed for 4 hours after washing with 3% 
BSA in PBS. After washing away the unbound primary antibody with PBS three times, cells were 
incubated with a fluorophore-tagged secondary antibody for one hour, and washed with PBS three 
times at room temperature prior to nuclear staining with ProLong Gold antifade reagent with DAPI 
(Life Technologies, Eugene, OR, USA). For the immunofluorescence staining of MCF-7 cells with 
BCA2 and Rad51 primary antibodies, cells were fixed with acetone–methanol, 1:1 (v/v) prior to the 
incubation with antibodies and the nuclear staining. A Nikon A1rsi laser scanning confocal microscope 
with a Plan Apo λ 100X/NA 1.45 oil immersion objective was utilized for imaging the localization and 
expression of EdU and γH2AX as indicated by the secondary antibodies Alexa Fluor 647 anti-EdU and 
Alexa Fluor 488 anti-mouse IgG, respectively. The localization and expression of Rad51 and BCA2 
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were determined based on the excitation signals from Alexa Fluor 488 anti-rabbit and Alexa Fluor 555 
anti-goat IgG, along with DAPI excitation wavelength at 405 nm. 
2.11. Statistical Analysis 
The data from the clonogenic assay and RT-PCR were normalized to the control groups.  
The statistical significance was tested by multiple comparisons with the Bonferroni correction,  
using the ProStat statistical software package (Polysoftware, Pearl River, NY, USA). Error bars 
indicate standard deviations of triplicate runs. 
3. Results 
3.1. Erb-041 Decreased Estrogen Receptor α (ERα) Signaling While Inhibiting Breast Cancer 
Associated-Gene 2 (BCA2) Transcription 
To characterize the effect of Erb-041 on ERα-mediated signaling in MCF-7 cells, we separated cell 
lysates into soluble and chromatin-bound fractions for protein analysis (Figure 1A,B). We found that 
24 h incubation with Erb-041 not only decreased chromatin-bound ERα (Figure 1B, lane 2 vs. lane 1) 
but also diminished UVC-induced chromatin association of ERα in MCF-7 cells (Figure 1B, lane 3 vs. 
lane 4). In contrast, chromatin-bound ERβ was increased by Erb-041 in the absence or presence of 
radiation (Figure 1B, lanes 2 and 3 vs. lane 1). Concurrently, the levels of BCA2 transcripts were 
decreased by Erb-041, suggesting the ERβ agonistic effect of Erb-041 antagonizes ERα-mediated 
BCA2 transcription (Figure 1C). These results indicate that Erb-041 reduces ERα chromatin association 
and BCA2 transcription. 
3.2. Erb-041 Induced the Accumulation of Cells in S Phase and Potentiated DNA Synthesis, Reducing 
the Repair of Ultraviolet-Induced DNA Damage 
Next, we checked the cell cycle distribution (Figure 2A,B) as well as cell proliferation and DNA 
damage response (Figure 2C). UVC-induced G2/M accumulation at 24 h post-irradiation was 
compromised by the arrest and accumulation of cells in S phase upon Erb-041 pretreatment. Moreover, 
the EdU incorporation assay indicates that DNA synthesis decreased with time in the non-irradiated 
group while DNA synthesis in the irradiated group increased (Figure 2C, photos 1–3 vs. photos 4–6). 
Intriguingly, the number of γH2AX foci preferentially increased with time in the irradiated group 
compared with the non-irradiated group. This result suggests that pretreatment with Erb-041 arrests 
cells in S phase and compromises the intra-S-phase DNA damage checkpoint evoked by UVC,  
leading to fewer DNA double-stranded breaks generated from post-replication recombination repair. 
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Figure 1. Erb-041 suppressed UVC-induced chromatin association of ERα in response to 
ERβ upregulation. (A) MCF-7 cells were treated with Erb-041 for 24 h prior to irradiation, 
as indicated in panels (A–C). Cell lysates from exponentially growing MCF-7 cells were 
fractionated into chromatin-bound (B) and soluble (A) fractions. The samples were subjected 
to SDS-PAGE electrophoresis and immunoblotting using anti-ERα, ERβ, actin, lamin B1 
and β-tubulin antibodies. The latter two blots were set as internal controls for the proteins 
expressed in the chromatin-bound and soluble fractions; (C) The mRNA levels of BCA2 
were analyzed using real-time RT-PCR. GAPDH was used as a loading control. The error 
bars represent standard deviations in this figure, as well as in all the other graphical figures. 
* denotes significant difference between control and experimental groups with p < 0.05  
(n = 3 for all measurements). Description of experimental conditions: lanes 1, cells without 
any treatment (denoted by Cont); lanes 2, cells incubated with 40 μg/mL Erb-041 for 24 h 
(denoted by Erb); lanes 3, cells incubated with 40 μg/mL Erb-041 for 24 h before UVC 
irradiation at the energy irradiance of 10 J/m2 (denoted by E+UV); lanes 4, cells irradiated by 
10 J/m2 UVC (denoted by UV). 
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Figure 2. Erb-041 mediated cell cycle arrest in S phase and potentiated UV-induced DNA 
synthesis (A) MCF-7 cells were treated with Erb-041 for 24 h prior to UVC irradiation. 
After irradiation, exponentially growing cells were further incubated for 24 h prior to 
overnight ethanol fixation. The amount of DNA in each cell was measured by FACS after 
propidium iodide staining; (B) Quantitative analysis of the cell cycle distribution in the 
setting described in (A); (C) DNA synthesis and damage were assayed by immunofluorescence 
staining with the nucleotide analog, EdU, as well as anti-γH2AX antibody. After being 
treated with Erb-041 for 24 h, cells continued to undergo 30 min EdU incorporation,  
which was terminated by PBS wash and medium replacement. Cell irradiation was then 
carried out prior to fixation and subsequent incubation with anti-EdU reaction buffer,  
anti-γH2AX antibody, the designated fluorophore antibody and DAPI. EdU incorporation 
was represented by the purple fluorescence of Alexa Fluor 647 while γH2AX foci and the 
cell nuclei were indicated by the green fluorescence of Alexa Fluor 488 and DAPI, 
respectively. Description of experimental conditions: image #1, cells without any treatment; 
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image #2, cells irradiated by 10J/m2 UVC and incubated for 30 min after irradiation;  
image #3, cells irradiated by 10J/m2 UVC and incubated for 2 h after irradiation; image #4, 
cells incubated with 40 μg/mL Erb-041 for 24 h; image #5, cells incubated with 40 μg/mL 
Erb-041 for 24 h before the UVC irradiation and 30 min post-irradiation incubation;  
image #6, cells incubated with 40 μg/mL Erb-041 for 24 h before the UVC irradiation and 
two-hour post-irradiation incubation. 
3.3. Erb-041 Exacerbated UV-induced DNA Damage through Reduction of BCA2 Expression and 
Mitigation of DNA Damage Response 
In regard to Erb-041-induced S-phase cell population, the S phase-specific DNA repair proteins 
including FANCD2 and Rad51 were upregulated in the chromatin-bound fractions without evoking 
Chk1 and H2AX phosphorylation (Figure 3B, lane 2 vs. lane 1). In contrast, chromatin-bound BCA2 
was decreased by Erb-041 in both its ubiquitinated and non-ubiquitinated forms (Figure 3B, lane 2 vs. 
lane 1). When cells were exposed to UVC, BCA2 was highly ubiquitinated and stably associated with 
chromatin, while phospho-Chk1, FANCD2 and Rad51 were also increased in association with 
chromatin in response to UV-induced DNA damage (Figure 3B, lane 4 vs. lane 1). However, DDR was 
diminished by pretreatment with Erb-041, leading to more diffused γH2AX, indicative of unresolved 
and unchecked DNA damage (Figure 3B, lane 3 vs. lane 4). Upon Erb-041 pretreatment, UVC-induced 
BCA2 ubiquitination was destabilized as ubiquitinated BCA2 dissociated from chromatin and was 
retained in the soluble fraction (Figure 3A,B, lanes 3 vs. lanes 4). Along with BCA2 solubilization, 
FANCD2, phospho-Chk1 and Rad51 (Figure 3A,B, lanes 3 vs. lanes 4) were also solubilized upon 
Erb-041 pretreatment. This result indicates that BCA2 may play a role in mediating Erb-041- modulated 
DNA damage response and repair. 
 
Figure 3. Erb-041 inhibited the chromatin association of BCA2 and reduced UV-induced 
DDR protein expression. After Erb-041 pretreatment or/and irradiation, exponentially growing 
MCF-7 cells were lysed and the cell lysates were fractionated and subjected to SDS-PAGE 
and immunoblotting with the indicated antibodies. Description of experimental conditions: 
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Lanes 1, cells without any treatment (denoted by Cont); lanes 2, cells incubated with  
40 μg/mL Erb-041 for 24 h (denoted by Erb-041); lanes 3, cells incubated with 40 μg/mL 
Erb-041 for 24 h before UVC irradiation at the energy irradiance of 10 J/m2 (denoted by 
E+UV); lanes 4, cells irradiated by 10J/m2 UVC (denoted by UV). Protein molecular 
weights at 35 and 55 KD indicate the non-ubiquitinated and polyubiquitinated BCA2. 
3.4. BCA2 Knockdown Intrinsically Induced DNA Damage Response and Impeded the Repair of  
UV-Induced DNA Damage 
To investigate the effect of BCA2 on DNA damage response and repair, BCA2-targeted siRNA was 
used to specifically knock down BCA2 (Figure 4A). Interestingly, the down-regulation of BCA2 
transcripts through siRNA transfection was accompanied by a significant decrease in ATM mRNA.  
On the other hand, DDR proteins, phospho-1981Ser-ATM, Rad51 and γH2AX, were increased along 
with a substrate of BCA2 ubiquitin ligase, p21, in MCF-7 cells upon BCA2 knockdown (Figure 4B). 
With respect to the insignificant up-regulation of Rad51 mRNA detected after BCA2 knockdown, 
BCA2 was hypothesized to regulate phospho-1981Ser-ATM and Rad51 not at the transcriptional level 
but at the posttranslational level. These results indicate that BCA2 may be essential for maintaining 
genomic stability via regulation of the turnover rates of DDR proteins and cell cycle checkpoint. 
*      *
  
(A) (B) 
Figure 4. BCA2 knockdown up-regulated several DDR proteins. (A) Transcriptional levels 
of BCA2, ATM and Rad51 genes were analyzed with quantitative real-time PCR at 72 h 
post-transfection with scrambled or BCA2-targeted siRNAs; (B) Replicate cultures of 
MCF-7 cells were transfected with siRNA against BCA2 or non-targeting control siRNA 
prior to irradiation and post-irradiation incubation. At 2 h post-irradiation, cell extracts 
were isolated and analyzed by SDS-PAGE and immunoblotting with the indicated 
antibodies. * denotes significant difference between control siRNA- and BCA2 siRNA-treated 
groups with p < 0.05. 
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3.5. BCA2 Endogenously Interacted with γH2AX and Rad51 in Association with  
Ubiquitin-Mediated Degradation 
In regard to the fact that BCA2 contains a RING-finger domain that interacts and ubiquitinates 
substrates [16,28], we further investigated whether BCA2 participated in DDR via its interaction with 
proteins involved in DNA damage repair. MCF-7 cells were treated with the proteasome inhibitor, 
MG132, for five hours prior to immunoprecipitation assays (Figure 5A,B; right IP lanes vs. left IP lanes). 
The endogenous BCA2 was fractionated and immunoprecipitated by the anti-BCA2 antibody, and the 
endogenous γH2AX and Rad51, along with the known substrate, p21, were co-immunoprecipitated 
(Figure 5A,B). Without marked, detectable upregulation of non-phosphorylated H2A, this result 
suggests that γH2AX could be a specific substrate for BCA2 in addition to Rad51 in the process of 
maintaining genome integrity and stability (Figure 5A). 
  
(A) (B) 
Figure 5. BCA2 interacts with γH2AX and Rad51. (A,B) MCF-7 cells were exposed to  
20 μM MG132 for 5 h and collected for immunoprecipitation using goat serum or anti-goat 
BCA2 antibody along with Protein A/G PLUS Agarose IP Reagent. The precipitated 
proteins were fractionated and subject to SDS-PAGE and immunoblotting with the 
indicated antibodies. Description of experimental conditions: chr, the chromatin-bound 
fraction of cell lysates; sol, the soluble fraction of cell lysates. 
3.6. Rad51 Protein Degradation May Be Preceded by the Nuclear Co-Localization of BCA2 and 
Rad51 Under Co-Treatment with Erb-041 and UVC 
The effect of Erb-041 on BCA2 interaction with Rad51 was assessed by immunofluorescence 
staining (Figure 6A). Based on the confocal microscope images, Erb-041 increased the expression of 
Rad51 (Figure 6A, image 7 vs. image 3), and subsequent irradiation resulted in the strong nuclear  
co-localization of BCA2 and Rad51 (Figure 6A, image 16 vs. image 8). Combined with the observation 
of Erb-041-mediated dissociation of BCA2 from chromatin (Figure 3A,B, lanes 3), this result indicates 
that Erb-041 impaired DDR partially via BCA2 interaction with Rad51 and the concurrent dissociation 
from chromatin. To study the consequence of BCA2 interaction with Rad51, we transfected HEK293T/17 
cells with a pCMV-BCA2-Flag construct in the absence of MG132 (Figure 6B). When recombinant 
BCA2 was gradually overexpressed in HEK293T/17 cells, the levels of endogenous Rad51 decreased 
in a BCA2 overexpression-dependent manner. This suggests that Rad51 may be targeted for  
ubiquitin-mediated degradation by BCA2, leading to compromised DNA repair via the HR pathway. 
Biomedicines 2015, 3 194 
 
 
A                       DAPI                   BCA2                   Rad51                 Merge    
Control
Erb-041
Erb-041+UV
UV
(2) Soluble fx Chromatin-bound fx 
1 2 3 4
5 6 7 8
9 10 11 12
13 14 15 16
10μm
 
 B 
 
Figure 6. Erb-041 potentiated BCA2 and Rad51 nuclear co-localization in association with 
ubiquitin-mediated Rad51 degradation. (A) MCF-7 cells under different experimental 
conditions were fixed and immunostained with anti-BCA2 and Rad51 antibodies prior the 
staining with Alexa Fluor 488 anti-goat, Alexa Fluor 555 anti-rabbit IgG, and the nuclear 
stain, DAPI, for confocal microscopic imaging; (B) The pCMV-BCA2-Flag or pcDNA3 
vector was transfected into HEK293T/17 cells. The cells were lysed 48 hours later, and the 
cell lysates were subject to SDS-PAGE and immunoblotting with anti-Rad51, actin and 
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FLAG antibodies. Description of experimental conditions: Control, cells without any 
treatment; Erb-041, cells incubated with 40 μg/mL Erb-041 for 24 h; UV, cells irradiated 
by 10 J/m2 UVC; Erb-041+UV, cells incubated with 40 μg/mL Erb-041 for 24 h before 
UVC irradiation at the energy irradiance of 10J/m2; first-lane images, DAPI immunofluorescence 
under different experimental conditions; second-lane images, anti-BCA2 immunofluorescence 
under different experimental conditions; third-lane images, anti-Rad51 immunofluorescence 
under different experimental conditions; fourth-lane images, merged immunofluorescence 
under the different experimental conditions. 
4. Discussion 
About a decade ago, researchers found that the prognosis for patients with ER-positive invasive 
breast cancers was better than that for patients with ER-negative non-aggressive cancers. The difference in 
prognosis correlated with BCA2 over-expression, which alternatively promotes the cell death of  
ER-positive breast cancers in association with functional DNA damage checkpoints, leading to 
negative regional recurrence of breast cancers [11]. In the present study, we have identified the role of 
BCA2 in maintaining the genomic integrity of ER-positive MCF-7 cells, and revealed a mechanism by 
which an ERβ agonist compromised BCA2-mediated DNA damage response and repair. It was found 
that Erb-041 inhibited chromatin association of ERα, leading to the reduced expression of BCA2.  
In support of our observation, ERα has been reported to bind to the estrogen response element of 
BCA2 and promote the gene transcription of p21 [12,29]. Through the association with cyclin−cdk 
complexes, p21 mediates cell cycle checkpoints at G1/S and G2/M transitions, thus permitting DNA 
repair to take place [30,31]. As ubiquitination of p21 by BCA2 promotes p21 proteosomal degradation,  
the stabilization of chromatin-bound BCA2 following UV irradiation was hypothesized to facilitate the 
activation of DNA damage checkpoints (because of free/unbound nuclear p21 to halt the cell cycle) [13]. 
Correspondingly, UV-induced lethal DNA damage was increased by Erb-041 pretreatment along with 
downregulation of chromatin-bound BCA2, suggesting that Erb-041 may potentiate UV-induced DNA 
damage via abrogation of cell cycle checkpoints. As expected, DNA synthesis in Erb-041-pretreated cells 
was less impeded by UV irradiation, compared to non-treated cells. 
Erb-041-mediated chromatin dissociation of BCA2 attenuated the cells’ DNA damage response and 
repair in intra S phase. Similar to BCA2 silencing, Erb-041 increased the expression of Rad51 and 
FANCD2 in the cells’ chromatin-bound fraction. When cells are incur to UV damage during DNA 
synthesis, the UV-induced oxidative DNA adducts can be converted to DNA DSBs during replication [32]. 
Some replication-coupled recombination repair pathways, such as the Fanconi Anemia pathway and 
homologous recombination are thus activated to repair post-replication DSBs by protein modification, 
including phosphorylation and ubiquitination [33,34]. Our results show that two crucial proteins in the 
FA and HR pathways, i.e., FANCD2 and Rad51, were decreased by Erb-041 pretreatment in the 
chromatin-bound fraction of MCF-7 cell lysates upon UV irradiation. Consistent with the regulation of 
DDR protein expression, the distribution of γH2AX becomes increasingly diffuse, following Erb-041 
pretreatment plus irradiation, compared with irradiation alone. 
Interestingly, BCA2 silencing intrinsically increased γH2AX, Rad51 and phospho-ATM, suggesting 
the involvement of BCA2 in DNA damage response and repair presumably via ubiquitination. During 
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the process of DNA repair, histone H2AX is often monoubiquitinated by RING-finger proteins and 
phosphorylated by ATM, thus recruiting DDR proteins to chromatin for repairing DNA double-stranded 
breaks [35–37]. Our results demonstrated that BCA2 can interact with Rad51 and γH2AX, presumably 
leading to Rad51 co-localization with the sites of double-stranded breaks. Moreover, the interaction of 
BCA2 and Rad51 highlights the role of BCA2 in maintaining genomic stability during de novo synthesis. 
On the contrary, Erb-041-induced BCA2 solubilization from chromatin is expected to accelerate 
Rad51 degradation upon BCA2-mediated ubiquitination. To summarize, this study describes a novel 
mechanism for treating ER-positive breast cancers using Erb-041 or drugs that share similar functions. 
Taken together, the present study shows the mechanism by which UV-induced DNA damage 
response and repair can be inhibited by an ERβ agonist that has been linked to ERα-dependent 
signaling. As illustrated in Figure 7 (the Proposed Working Model), the basal level of ERα promotes 
DNA damage response and repair, thus maintaining cell survival after irradiation by stabilizing the 
chromatin association of Rad51 and BCA2. With Erb-041 pretreatment, UV-induced DNA damage 
response and repair are presumably compromised by the failure to ubiquitinate H2AX and a 
consequent decrease in Rad51 chromatin association. This study suggests a role of ER/BCA2 signaling 
in facilitating DNA repair and the potential for targeting BCA2 to sensitize ER-positive cells to 
oxidative DNA damage induced by UV, X-ray radiation, or chemotherapeutic agents.  
PI3K/Akt  
 
Figure 7. Proposed working model. In response to UVC, MCF-7 cells increase the 
ubiquitination activity and chromatin-binding ability of BCA2 through AKT-mediated BCA2 
activation [28,38]. The association of BCA2 with γH2AX incites a BCA2/H2AX/ATM 
axis, initiating the DDR and controlling breast cancer cell sensitivity. The importance of 
Erb-041 in suppressing DNA recombination repair through BCA2 inhibition is based on 
the mitigatory effect of Erb-041 on AKT activation and ERα-mediated BCA2 transcription [4]. 
By pretreating MCF-7 cells with Erb-041, UV-induced chromatin-bound Rad51 and BCA2 
became solubilized, leading to the abolition of DNA repair. 
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5. Conclusions 
Estrogen receptors have long been targeted for breast cancer treatment. Anti-estrogenic drugs have 
been reported to synergize the growth inhibitory effect of ionizing radiation [39]. The Erb-041-mediated 
reduction of chromatin-bound BCA2 increased the levels of chromatin-bound γH2AX upon UVC 
irradiation, indicating an important role of BCA2 in regulating DNA damage response and repair.  
In response to estrogen-induced oxidative DNA damage, ER-positive MCF-7 cells timely initiated 
γH2AX foci formation in the presence of an inherently corresponding effector, BCA2, indicating its 
important role in eliminating DNA damage and promoting cell proliferation [40]. In this study,  
we demonstrated that Rad51 and γH2AX interact with BCA2 in correlation with the chromatin-binding 
capability of BCA2. BCA2 knockdown increased the number of DSBs, ATM phosphorylation, and the 
expression of proteins involved in DNA homologous recombination repair. Treatment with UVC also 
resulted in a large number of DNA DSBs in MCF-7 cells under BCA2 knockdown. This indicates a 
role of BCA2 in maintaining genomic stability and mediating DDR towards endogenous and external 
genotoxic stress, such as replication-/transcription-coupled and chemical-induced DNA DSBs. 
Disregarding the cancer type and background, including ATM, BRCA2 and p53 mutations or PTEN 
(phosphatase and tensin homolog) loss, the inhibition of BCA2 by either anti-ERα endocrine therapy 
or anti-BCA2 gene therapy holds promise for the neoadjuvant treatment of breast cancers as most of them 
possess functional BCA2. 
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